View Item 

Show simple item record

Pimecrolimus in dermatology: atopic dermatitis and beyond

dc.contributor.authorGisondi, Paoloen_US
dc.contributor.authorEllis, Charles N.en_US
dc.contributor.authorGirolomoni, Giampieroen_US
dc.date.accessioned2010-06-01T20:03:50Z
dc.date.available2010-06-01T20:03:50Z
dc.date.issued2005-08en_US
dc.identifier.citationGisondi, Paolo; Ellis, Charles N.; Girolomoni, Giampiero (2005). "Pimecrolimus in dermatology: atopic dermatitis and beyond." International Journal of Clinical Practice 59(8): 969-974. <http://hdl.handle.net/2027.42/73190>en_US
dc.identifier.issn1368-5031en_US
dc.identifier.issn1742-1241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73190
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16033622&dopt=citationen_US
dc.description.abstractPimecrolimus is a calcineurin inhibitor developed for the topical therapy of inflammatory skin diseases, particularly atopic dermatitis (AD). Pimecrolimus selectively targets T cells and mast cells. Pimecrolimus inhibits T-cell proliferation, as well as production and release of interleukin-2 (IL-2), IL-4, interferon-γ and tumour necrosis factor-α. Moreover, pimecrolimus inhibits mast cell degranulation. In contrast to tacrolimus, pimecrolimus has no effects on the differentiation, maturation and functions of dendritic cells. In contrast to corticosteroids, pimecrolimus does not affect endothelial cells and fibroblasts and does not induce skin atrophy. Given the low capacity of pimecrolimus to permeate through the skin, it has a very low risk of systemic exposure and subsequent systemic side-effects. In different randomised controlled trials, topical pimecrolimus as cream 1% (Elidel ® ) has been shown to be effective, well tolerated and safe in both adults and children with mild to moderate AD. In addition, pimecrolimus has been successfully used in inflammatory skin diseases other than AD, including seborrheic dermatitis, intertriginous psoriasis, lichen planus and cutaneous lupus erythematosus.en_US
dc.format.extent109535 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rightsBlackwell Publishing Ltd., 2005en_US
dc.subject.otherPimecrolimusen_US
dc.subject.otherInflammatory Skin Diseaseen_US
dc.subject.otherTherapyen_US
dc.subject.otherAtopic Dermatitisen_US
dc.titlePimecrolimus in dermatology: atopic dermatitis and beyonden_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum  University of Michigan Medical School, Ann Arbor, MI, USA, Section of Dermatology, Department of Biomedical and Surgical Sciences,en_US
dc.contributor.affiliationother  Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy, Department of Dermatology,en_US
dc.contributor.affiliationother  University of Verona, Verona, Italyen_US
dc.identifier.pmid16033622en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73190/1/j.1368-5031.2005.00587.x.pdf
dc.identifier.doi10.1111/j.1368-5031.2005.00587.xen_US
dc.identifier.sourceInternational Journal of Clinical Practiceen_US
dc.identifier.citedreferenceMarsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12: 618 – 22.en_US
dc.identifier.citedreferenceGrassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721 – 30.en_US
dc.identifier.citedreferenceGraham-Brown RAC, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 2003; 57: 319 – 27.en_US
dc.identifier.citedreferenceHoetzenecker W, Meingassner JG, Ecker R et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673 – 84.en_US
dc.identifier.citedreferenceKalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003; 133: 350 – 9.en_US
dc.identifier.citedreferencePanhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langherans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345 – 52.en_US
dc.identifier.citedreferenceMeingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity in contrast to tacrolimus and cyclosporine A. J Invest Dermatol 2003; 121: 231.en_US
dc.identifier.citedreferenceQueille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507 – 13.en_US
dc.identifier.citedreferenceBillich A, Aschauer H, AszÒdi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than CS and tacrolimus. Int J Pharmacol 2004; 269: 29 – 35.en_US
dc.identifier.citedreferenceLeung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151 – 60.en_US
dc.identifier.citedreferenceGirolomoni G, Abeni D, Masini C et al. The epidemiology of atopic dermatitis in Italian schoolchildren. Allergy 2003; 58: 420 – 5.en_US
dc.identifier.citedreferenceFivenson D, Arnold RJ, Kaniecki DJ et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8: 333 – 42.en_US
dc.identifier.citedreferenceEllis CN, Drake LA, Prendergast MM et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46: 361 – 70.en_US
dc.identifier.citedreferenceEichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495 – 504.en_US
dc.identifier.citedreferenceEichenfield LF, Lucky AW, Langley RG et al. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol 2005; 44: 70 – 5.en_US
dc.identifier.citedreferenceLeo HL, Bender BG, Leung SB et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004; 114: 691 – 3.en_US
dc.identifier.citedreferenceKempers S, Boguniewicz M, Carter E et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515 – 25.en_US
dc.identifier.citedreferenceKapp A, Papp K, Bingham A et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277 – 84.en_US
dc.identifier.citedreferencePapp KA, Werfel T, Folster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005; 52: 240 – 6.en_US
dc.identifier.citedreferenceMeurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365 – 72.en_US
dc.identifier.citedreferenceLuger TA, Lahfa M, Folster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004; 15: 169 – 78.en_US
dc.identifier.citedreferenceMeingassner JG, Grassberger M, Fahrngruber H et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568 – 76.en_US
dc.identifier.citedreferenceWahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110 ( 1 Part 1 ): e2.en_US
dc.identifier.citedreferencePapp KA, Breuer K, Meurer M et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005; 52: 247 – 53.en_US
dc.identifier.citedreferenceGribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731 – 8.en_US
dc.identifier.citedreferenceRigopoulos D, Ioannides D, Kalogeromitros D et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004; 151: 1071 – 5.en_US
dc.identifier.citedreferenceBelsito DV, Fowler JF Jr, Marks JG Jr et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73: 31 – 8.en_US
dc.identifier.citedreferenceEsquivel-Pedraza L, Fernandez-Cuevas L, Ortiz-Pedroza G et al. Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004; 150: 771 – 3.en_US
dc.identifier.citedreferenceDissemond J, Schroter S, Franckson T et al. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br J Dermatol 2004; 150: 782 – 4.en_US
dc.identifier.citedreferenceKreuter A, Gambichler T, Breuckmann F et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51: 407 – 10.en_US
dc.identifier.citedreferenceLim SJ, Love EW. Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J Drugs Dermatol 2004; 3: 563 – 4.en_US
dc.identifier.citedreferenceMayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322 – 3.en_US
dc.identifier.citedreferenceZiemer M, Gruhn B, Thiele JJ, Elsner P. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol 2004; 50: 946 – 8.en_US
dc.identifier.citedreferenceMrowietz U, Wustlich S, Hoexter G et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003; 83: 351 – 3.en_US
dc.identifier.citedreferenceThaci D, Steinmeyer K, Ebelin ME et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 2003; 207: 37 – 42.en_US
dc.identifier.citedreferenceRappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119: 876 – 87.en_US
dc.identifier.citedreferenceHarbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334 – 6.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1368-5031.2005.00587.x.pdf
Size:
106.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.